Enhancement of activity of 1α,25-dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an α-tocopherol ester of all-trans retinoic acid

Blood

Volumn 87, Issue 8, 1996, Pages 3384-3394

  Makishima, Makoto ^a   Kanatani, Yasuhiro ^a   Yamamoto Yamaguchi, Yuri ^a   Honma, Yoshio ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CALCITRIOL; DIMETHYL SULFOXIDE; DRUG DERIVATIVE; GROWTH INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOIC ACID; TOCORETINATE; CD11B ANTIGEN; NITROBLUE TETRAZOLIUM;

ACUTE MONOCYTIC LEUKEMIA; ARTICLE; CANCER STEM CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; CELL STRAIN HL 60; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; HISTIOCYTIC LYMPHOMA; HUMAN; MYELOMONOCYTIC LEUKEMIA; PATHOLOGY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CALCITRIOL; CELL DIFFERENTIATION; CELL DIVISION; DIMETHYL SULFOXIDE; DRUG COMBINATIONS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GROWTH INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LYMPHOMA, LARGE-CELL; TETRADECANOYLPHORBOL ACETATE; TRETINOIN; TUMOR CELLS, CULTURED; TUMOR STEM CELLS; VITAMIN E;

EID: 0029664540     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.8.3384.bloodjournal8783384     Document Type: Article

References (57)

1. Warrell RP Jr: Applications for retinoids in cancer therapy. Semin Hematol 31:1, 1994 (suppl 5)
2. Warrell RP Jr, de The H, Wang Z-Y, Degos L: Acute promyelocytic leukemia. New Engl J Med 329:177, 1993
3. Tallman MS: All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies. Semin Hematol 31:38, 1994 (suppl 5)
4. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292, 1992
5. Warrell RP Jr: Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 82:1949, 1993
6. Hashimoto Y, Shudo K: Retinoids and their nuclear receptors. Cell Biol Rev 25:209, 1991
7. Dawson MI, Elstner E, Kizaki M, Chen D-L, Pakkala S, Kerner B, Koeffler HP: Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway. Blood 84:446, 1994
8. Takahashi N, Breitman TR: induction of differentiation and covalent binding to proteins by the synthetic retinoids Ch55 and Am80. Arch Biochem Biophys 314:82, 1994
9. Peck R, Bollag W: Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 27:53, 1991
10. Breitman TR, Chen Z-X, Takahashi N: Potential applications of cytodifferentiation therapy in hematologic malignancies. Semin Hematol 31:18, 1994 (suppl 5)
11. 3 co-operate to promote differentiation of the human promyeloid leukemia cell line HL60 to monocytes. Leukemia 8:806, 1994
12. 3 and either retinoic acid, sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce monocytoid differentiation of the human myeloid leukemia cell line HL-60. Biomed Pharmacother 46:313, 1992 (abstr)
13. Meydani M: Vitamin E. Lancet 345:170, 1995
14. Turley JM, Sanders BG, Kline K: RRR-α-Tocopheryl succinate modulation of human promyelocytic leukemia (HL-60) cell proliferation and differentiation. Nutr Cancer 18:201, 1992
15. Prasad KN, Edward-Prasad J: Effects of tocopherol (vitamin E) acid succinate on morphological alterations growth inhibition in melanoma cells in culture Cancer Res 42:550, 1982
16. Cook MG, McNamara P: Effect of dietary vitamin E on dimethylhydrazine-induced colonic tumors in mice. Cancer Res 40:1329, 1980
17. Perchellet J-P, Owen MD, Posey TD, Orten DK, Schneider BA: Inhibitory effects of glutathione level-raising agents and D-α-tocopherol on ornithine decarboxylase induction and mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis 6:567, 1985
18. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, Yang CS, Zheng S-F, Gail M, Li G-Y, Yu Y, Liu B-Q, Tangrea J, Sun Y-H, Liu F, Fraumeni JF Jr, Zhang Y-H, Li B: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483, 1993
19. Taylor PR, Li B, Dawsey SM, Li J-Y, Yang CS, Guo W, Blot WJ, the Linxian Nutrition Intervention Trials Study Group: Prevention of esophageal cancer: The nutrition intervention trials in Linxian, China. Cancer Res 54:2029s, 1994 (suppl)
20. Yasuno Y, Kishimoto S, Yamanishi K, Konishi K, Oka F, Oonishi M, Kagami K, Oki M, Maeda M, Sasaki Y, Komori Y, Wakabayashi S, Miura H, Inoue Y, Miyashita A, Tamaoki K, Okuda R, Ryu F: Evaluation of the effects of L-300 ointment in the treatment of intractable skin ulcers. Rinsho-iyaku (in Japanese) 6:2481, 1990
21. Collins SJ, Gallo RC, Gallagher RE: Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270:347, 1977
22. Sundström C, Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line. Int J Cancer 17:565, 1976
23. Minowada J: Immunology of leukemic cells, in Grunz F, Henderson E (eds): Leukemia. New York, NY, Grune & Stratton, 1982, p 119
24. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26:171, 1980
25. Nagai M, Seki S, Kitahara T, Abe T, Minato K, Watanabe S, Shimoyama M: A novel human myelomonocytoid cell line, P39/ Tsugane, derived from overt leukemia following myelodysplastic syndrome. Jpn J Cancer Res (Gann) 75:1100, 1984
26. Hirose M, Minato K, Tobinai K, Shimoyama M, Watanabe S, Abe T: A novel monocytoid cultured cell line, P31/Fujioka, derived from acute monoblastic leukemia. Jpn J Cancer Res (Gann) 73.735, 1982
27. Makishima M, Honma Y, Hozumi M, Sampi K, Hattori M, Ishikawa I, Ogura H, Motoyoshi K: Effects of novel uracil analogs on proliferation and differentiation of human myeloid leukemia cells. Exp Hematol 20:879, 1992
28. + leukemic cells transfected with differentiation-stimulating factor/leukemia inhibitory factor receptor cDNA. Blood 85:217, 1995
29. Berenbaum MC: What is synergy? Pharmacol Rev 41:93, 1989
30. Chen Z-X, Breitman TR: Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 54:3494, 1994
31. Hozumi M: Fundamentals of chemotherapy of myeloid leukemia by induction of leukemia cell differentiation. Adv Cancer Res 38:121, 1983
32. Takenaga K, Honma Y, Hozumi M: Inhibition of differentiation of mouse myeloid leukemia cells by phenolic antioxidants and α-tocopherol. Jpn J Cancer Res (Gann) 72:104, 1981
33. 3 by human monocytic leukemia cells. FEBS Lett 309:399, 1992
34. Bikle DD: Clinical counterpoint: Vitamin D: New actions, new analogs, new therapeutic potential. Endocrine Rev 13:765, 1992
35. Hamada H, Sakyo K, Tanaka H, Ogawa O, Nishiki K: Effect of tocoretinate on migration of cells. Pharmacometrics (in Japanese) 43:97, 1992
36. Sakyo K, Otsuka N, Hamada H, Nakaya N, Nakazawa T, Nakahara Y, Naruke T, Nishiki K, Ito A, Mori Y: Effect of tocoretinate on proliferation of normal human skin fibroblasts. Pharmacometrics (in Japanese) 43:103, 1992
37. 3. Proc Am Ass Cancer Res 36:348, 1995 (abstr)
38. 14C-tocoretinate in rats and dogs. Pharmacometrics (in Japanese) 43:1, 1992
39. Kamm JJ: Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids. J Am Acad Dermatol 6:652, 1982
40. Lowe NJ, David M: New retinoids for dermatologic diseases. Uses and toxicity. Dermatol Clin 6:539, 1988
41. Harada Y, Narita H, Kashiwagi H, Misawa N, Takagi H, Takita S, Inomata N: Acute toxicity study of tocoretinate in mice, rats and dogs. Pharmacometrics (in Japanese) 43:7, 1992
42. Okazaki S, Mochizuki M, Masuda T, Takagi H, Takita S, Inomata N: A 12-month oral toxicity study of tocoretinate in rats. Pharmacometrics (in Japanese) 43:251, 1992
43. Ohta R, Hashimoto Y, Mizutani M, Misawa N, Inomata N: Reproductive and developmental toxicity study of tocoretinate (I). Effects on reproductive function and fertility in rats (segment I study). Pharmacometrics (in Japanese) 43:303, 1992
44. Tanaka N, Murakami Y, Noguchi O, Narita H, Hamada S, Ohashi M, Misawa N, Inomata N: Reproductive and developmental toxicity study of tocoretinate (III). Teratological study in rabbits by oral administration. Pharmacometrics (in Japanese) 43:323, 1992
45. Murakami Y, Ogasawara H, Sakauchi N, Narita H, Hamada S, Ohashi M, Noguchi O, Tanaka N, Misawa N, Inomata N: Reproductive and developmental toxicity study of tocoretinate (IV). Administration to female rats during the perinatal and postnatal periods. Pharmacometrics (in Japanese) 43:329, 1992
46. Besa EC, Abrahm JL, Bartholomew MJ, Hyzinski M, Nowell PC: Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. Am J Med 89:739, 1990
47. Muindi JRF, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RP Jr: Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia Cancer Res 52:2138, 1992
48. Cornic M, Delva L, Guidez F, Balitrand N, Degos L, Chomienne C: Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 52:3329, 1992
49. Rigas JR, Francis PA, Muindi JRF, Kjis MG, Huselton C, DeGrazia F, Orazem JP, Young CW, Warrell RP Jr: Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 85:1921, 1993
50. 14C-tocoretinate in rats and dogs. Pharmacometrics (in Japanese) 43:205, 1992
51. 3: In vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69:1399, 1985
52. Akiyama H, Nakamura N, Nagasaka S, Sakamaki H, Onozawa Y: Hypercalcaemia due to all-trans retinoic acid. Lancet 339:308, 1992
53. Sakakibara M, Ichikawa M, Amano Y, Matsuzawa S, Agematsu K, Mori T, Koike K, Nakahata T, Komiyama A: Hypercalcemia associated with all-trans-retinoic acid in the treatment of acute promyelocytic leukemia Leuk Res 17:441, 1993
54. Suzumiya J, Asahara F, Katakami H, Kimura N, Hisano S, Okumura M, Ohno R: Hypercalcaemia caused by all-trans retinoic acid treatment of acute promyelocytic leukaemia: Case report. Eur J Haematol 53:126, 1994
55. 2/day. Eur J Haematol 55:275, 1995
56. Cassidy J, Lippman M, Lacroix A, Peck G: Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur J Cancer Clin Oncol 18:925, 1982
57. Villablanca JG, Khan AA, Avramis VI, Reynolds CP: Hypercalcemia: A dose-limiting toxicity associated with 13-cis-retinoic acid. Am J Pediatr Hematol Oncol 15:410, 1993